kyron.bio Partners with Servier to Advance Precision Glycoengineering for Next-Generation Antibody Therapeutics
Key Insights
kyron.bio (search) announced a strategic partnership with Servier to apply its proprietary glycoengineering platform to enhance antibody therapeutic performance through precise glycan control.
The collaboration involves Servier funding kyron.bio (search)'s research to glycoengineer a selected antibody, with Servier holding options for further development based on outcomes.
kyron.bio (search)'s platform addresses technical challenges in glycan engineering that have historically limited the use of precision glycosylation in drug design.
kyron.bio (search), a biotechnology company pioneering precision glycoengineering for antibody therapeutic development, has announced a strategic partnership with Servier, an international pharmaceutical group, to advance next-generation antibody therapeutics (search) through enhanced glycan control. The collaboration aims to demonstrate the potential of precision glycosylation to improve antibody efficacy, safety, and scalability across multiple disease areas.
Partnership Structure and Objectives
Under the partnership agreement, kyron.bio (search) will apply its proprietary glycoengineering technology to modify an antibody selected by Servier, with Servier funding the associated research activities. The collaboration is structured as a funded research effort where Servier will hold an option to explore additional antibody engineering and development opportunities based on the outcomes. Financial details of the agreement were not disclosed.
The partnership specifically targets demonstrating clear glycan control on Servier's antibody of interest for a predetermined N-glycoform. This approach represents a shift from treating glycans as "manufacturing noise" to engineering them as programmable parameters in antibody design.
Addressing Technical Challenges in Glycan Engineering
kyron.bio (search)'s platform addresses longstanding technical challenges that have limited the exploitation of glycan engineering in drug design. The company has developed a scalable, proprietary method to achieve comprehensive control over glycosylation, combining engineered Chinese hamster ovary (CHO) production systems with proprietary antibody-side modifications.
"Precision glycosylation represents a transformative approach in biologics development," said Dr. Emilia McLaughlin, founder and Chief Executive Officer of kyron.bio (search). "By engineering defined glycan profiles, therapeutic antibodies can be optimized for improved immune engagement, pharmacokinetics, and reduced variability."
Antibodies carry sugar structures (glycans) that influence immune effector functions, stability, pharmacokinetics, and batch-to-batch consistency. In conventional manufacturing, these glycans typically form heterogeneous mixtures, which can complicate efforts to optimize or reproduce specific biological behaviors.
Building on Previous Collaboration
The formal partnership builds on an existing relationship established through Servier's startup ecosystem. In 2024, kyron.bio (search) won Servier's Golden Ticket award, which provided invaluable support, mentorship, lab space, and scientific exchange during the company's early translational phase.
"Meeting kyron.bio (search) as a winner of Servier's Golden Ticket award has enabled our scientists to develop an understanding of the kyron.bio glycan engineering technology and its exciting possibilities in antibody drug design," said Dr. Emmanuel Nony, Director of External Innovation Europe at Servier. "This collaboration is opening new frontiers for antibody derivatives as well. Together, we are exploring innovative pathways to optimize drug design and production, with a shared commitment to bringing safer and more effective therapies to patients."
Company Development and Funding
kyron.bio (search) was founded in 2022 to commercialize technology developed through the French Entrepreneur First Program. In 2025, the company raised €5.5 million in a seed round from an experienced syndicate of venture investors including HCVC (search), Verve Ventures (search), Entrepreneurs First (search), and Saras Capital (search), along with private angel investors and the European Innovation Council (search).
The company has established its R&D base at Paris Biotech Santé in the Cochin Hospital, one of Paris's prominent life-science hubs. kyron.bio (search)'s strategy focuses on forming strategic drug design partnerships with pharmaceutical and biotech companies working on next-generation antibody therapeutics (search), while also developing in-house therapeutic programs.
Technology Applications and Market Potential
kyron.bio (search)'s glycoengineering platform leverages both proprietary cell-based systems and structure-guided design to unlock the potential of N-glycans (search) in drug development. The technology addresses therapeutic indications including oncology (search) and autoimmune diseases (search), areas where antibody performance and manufacturability can be decisive factors.
The partnership with Servier represents a significant validation of precision glycosylation as an investable and testable approach within pharmaceutical R&D, moving beyond academic glycobiology into industrial applications. The collaboration's success will be measured by kyron.bio (search)'s ability to deliver clear, reproducible control of the requested glycoform on Servier's chosen antibody in a scalable and transferable manner.